Atlas Trials

A Study of Furmonertinib Combined With Chemotherapy in the Treatment of NSCLC With Leptomeningeal Metastasis

Clinical trial NCT06339242 · UNKNOWN

Trial details

NCT number
NCT06339242
Sponsor
Jiangsu Province Nanjing Brain Hospital
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
NSCLC
Start date
2024-01-01
Primary completion
2025-07-01
Enrollment
30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.